RENA HAMAZASPYAN: Open Payments
NPI 1124391057 · LANGHORNE, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$942 in 18 payments from 9 companies in 2025. Trend: 2023 $347 · 2024 $716 · 2025 $942
Food & beverage: $942
| Company | Payments | Amount |
|---|---|---|
| Alnylam Pharmaceuticals Inc. | 4 | $176 |
| Novo Nordisk Inc | 3 | $150 |
| HEARTFLOW, INC. | 2 | $148 |
| AstraZeneca Pharmaceuticals LP | 1 | $125 |
| Gilead Sciences, Inc. | 1 | $117 |
| Medtronic, Inc. | 1 | $113 |
| Merck Sharp & Dohme LLC | 2 | $42 |
| PFIZER INC. | 2 | $38 |
| Novartis Pharmaceuticals Corporation | 2 | $32 |
Products named: Wegovy, FFRct, AIRSUPRA, AMVUTTRA, Descovy, COREVALVE EVOLUT R, ONPATTRO, VERQUVO.
Industry payments across PA — which companies pay providers there.
